The frequency of chronic liver disease (CLD) is rising
Ageing population expanding Programs to raise awareness of liver illness in the public and private sectors.
The Chronic Liver Disease (CLD) Therapeutics Market in the Middle East and Turkey is anticipated to reach US$ 1,015 million in 2021 and grow at a CAGR of 5.8% from 2021 to 2028.
Key Companies in the Middle East And Turkey Chronic Liver Disease Therapeutics Industry:
1. Hoffmann-La Roche AG:
Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar. Roche plans to purchase the TIB Molbiol Group, with a closing anticipated for the fourth quarter of 2021
2. Gilead Sciences, Inc.:
Built in 1987. Headquarters located in Foster City, California. The primary focus of Gilead Sciences' product portfolio is on HIV and hepatitis B and C. Gilead Sciences creates and sells treatments to treat infectious diseases that are life-threatening. This focus has since been widened to encompass cancer, lung and cardiovascular disorders, and C Arresto Biosciences, V Therapeutics, and Myogen.
